- Existing At-The-Market (ATM) program now
complete
- New Preliminary Base Shelf Prospectus Has Been
Filed
- Current Cash Position is Approximately $272 million
NYSE | TSX: ACB
EDMONTON, AB, Oct. 27, 2020 /PRNewswire/ - Aurora Cannabis Inc.
(the "Company" or "Aurora") (NYSE: ACB) (TSX: ACB),
the Canadian company defining the future of cannabinoids worldwide,
today announced it has completed the previously filed At-The-Market
("ATM") program. Because of this, the Company has filed a new
preliminary short form base shelf prospectus (the "Shelf
Prospectus") with securities regulators in each of the provinces of
Canada, except Quebec, and a corresponding shelf registration
statement on Form F–10 (the "Registration Statement") with the
United States Securities and Exchange Commission (the "SEC").
The base shelf prospectus when made final, will allow the
Company to make offerings of up to U.S.$500
million of common shares, preferred shares, warrants,
subscription receipts and debt securities, or any combination
thereof during the 25-month period that the base shelf prospectus
remains effective. The specific terms of any offering of
securities, including the use of proceeds from any offering, will
be set forth in a prospectus supplement to the Shelf Prospectus,
which will be filed with the applicable Canadian securities
regulatory authorities and the SEC. Aurora filed the Shelf
Prospectus in order to provide the Company with continued financial
flexibility going forward.
With the completion of the previously filed ATM program, the
Company currently has available cash resources of approximately
$272 million, in addition of undrawn
revolver capacity of approximately $11
million.
About Aurora
Aurora is a global leader in the cannabis industry serving both
the medical and consumer markets. Headquartered in Edmonton, Alberta, Aurora is a pioneer in
global cannabis dedicated to helping people improve their lives.
The Company's brand portfolio includes Aurora, Aurora Drift, San
Rafael '71, Daily Special, AltaVie, MedReleaf, CanniMed, Whistler,
and Reliva CBD. Providing customers with innovative, high-quality
cannabis products, Aurora's brands continue to break through as
industry leaders in the medical, performance, wellness and
recreational markets wherever they are launched. For more
information, please visit our website at www.auroramj.com.
Aurora's Common Shares trade on the TSX and NYSE under the
symbol "ACB", and is a constituent of the S&P/TSX Composite
Index.
Forward Looking Statements
This news release includes statements containing certain
"forward-looking information" within the meaning of applicable
securities law ("forward-looking statements").
Forward-looking statements are frequently characterized by words
such as "plan", "continue", "expect", "project", "intend",
"believe", "anticipate", "estimate", "may", "will", "potential",
"proposed" and other similar words, or statements that certain
events or conditions "may" or "will" occur. Forward-looking
statements made in this news release include statements regarding:
(i) the filing of the final base shelf prospectus; and (ii) the
Company's goals of achieving positive Adjusted EBITDA and positive
free cash flow. These forward-looking statements are only
predictions. Various assumptions were used in drawing the
conclusions or making the projections contained in the
forward-looking statements throughout this news release.
Forward-looking statements are based on the opinions, estimates and
assumptions of management in light of management's experience and
perception of historical trends, current conditions and expected
developments at the date the statements are made, such as current
and future market conditions, the ability to maintain SG&A
costs in line with current expectations, the ability to achieve
high margin revenues in the Canadian consumer market, the current
and future regulatory environment and future approvals and permits.
Forward-looking statements are subject to a variety of risks,
uncertainties and other factors that management believes to be
relevant and reasonable in the circumstances could cause actual
events, results, level of activity, performance, prospects,
opportunities or achievements to differ materially from those
projected in the forward-looking statements, including the risks
associated with: entering the U.S. market, the ability to realize
the anticipated benefits associated with the acquisition of Reliva,
achievement of Aurora's business transformation plan, general
business and economic conditions, changes in laws and regulations,
product demand, changes in prices of required commodities,
competition, the effects of and responses to the COVID-19 pandemic
and other risks, uncertainties and factors set out under the
heading "Risk Factors" in the Company's annual information form
dated September 24, 2020 (the
"AIF") and filed with Canadian securities regulators
available on the Company's issuer profile on SEDAR at www.sedar.com
and filed with and available on the SEC's website at www.edgar.gov.
The Company cautions that the list of risks, uncertainties and
other factors described in the AIF is not exhaustive and other
factors could also adversely affect its results. Readers are urged
to consider the risks, uncertainties and assumptions carefully in
evaluating the forward-looking statements and are cautioned not to
place undue reliance on such information. The Company is under no
obligation, and expressly disclaims any intention or obligation, to
update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise, except as
expressly required by applicable securities law.
The Company uses financial measures regarding itself, such as
Adjusted EBITDA, that do not have standardized meaning under the
International Financial Reporting Standards ("IFRS") and may
not be comparable to similar measures presented by other entities
("non-IFRS measures"). Further information relating to
non-IFRS measures, is set out in the Company's management
discussion and analysis for the three and twelve months ended
June 30, 2020 and 2019 under the
heading "Cautionary Statement Regarding Non-GAAP Performance
Measures" and the "Revenue" section for reconciliation to the IFRS
equivalent.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/aurora-cannabis-announces-filing-of-preliminary-base-shelf-prospectus-and-provides-update-on-balance-sheet-strength-301160264.html
SOURCE Aurora Cannabis Inc.